OncXerna Therapeutics Inc.

https://www.oncxerna.com

OncXerna is a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its targeted oncology therapeutic candidates. OncXerna is working to expand next-generation precision medicine to a larger group of cancer patients by leveraging the company’s Xerna™ platform to prospectively identify patients based on the dominant biology of their cancer. OncXerna’s approach pairs those patients with OncXerna’s clinical-stage therapeutic candidates and known mechanism of action that directly address these biologies, with the goal to substantially improve patient outcomes. The Xerna™ TME Panel uses proprietary RNA-based gene expression data and a machine learning-based algorithm to classify patients based on the interplay between angiogenic and immunogenic dominant biologies of the tumor microenvironment (TME), and has been developed as a clinical assay. The Xerna™ TME Panel is an investigational assay that has not been approved, and has not been demonstrated to be safe or effective for any use. *

	Start	2020-09-18 renamed
	Group	OncXerna Therapeutics (Group)
	Predecessor	Oncologie Inc. (US/CN)
	Industry	drug development
	Industry 2	cancer drug
	Person	Benjamin, Laura (Oncologie Inc 201802 CEO)

	Region	Waltham, MA
	Country	United States (USA)
	City	n. a.
		Address record changed: 2021-08-10

Basic data	Employees	n. a.

		* Document for »About Section«: Qiagen N.V.. (8/9/21). "Press Release: Qiagen and OncXerna Therapeutics Sign Licensing and Master Companion Diagnostic Agreements". Hilden, Waltham, MA & Germantown, MD.

		Record changed: 2023-07-10

Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x200px

More documents for OncXerna Therapeutics (Group)

[1] Qiagen N.V.. (8/9/21). "Press Release: Qiagen and OncXerna Therapeutics Sign Licensing and Master Companion Diagnostic Agreements". Hilden, Waltham, MA & Germantown, MD....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]